mckinleymedia

About mckinleymedia

This author has not yet filled in any details.
So far mckinleymedia has created 223 blog entries.
13 Apr, 2022

2022 AACR: Applying NeXT Liquid Biopsy™, an exome-scale platform, to monitor and discover somatic variants in a broad set of cancer types

2022 AACR: Applying NeXT Liquid Biopsy™, an exome-scale platform, to monitor and discover somatic variants in a broad set of cancer types Overview Circulating tumor cell-free DNA (ctDNA) has become a biomarker for prognosis and disease monitoring. However, studies typically utilize assays limited to a small set of genes that may miss biologically important [...]

13 Apr, 2022

2022 AACR: Exome-scale longitudinal tracking of emerging therapeutic resistance in GIST via analysis of circulating tumor DNA

2022 AACR: Exome-scale longitudinal tracking of emerging therapeutic resistance in GIST via analysis of circulating tumor DNA Overview Gastrointestinal stromal tumors (GIST) are lethal tumors characterized by constitutively activating mutations to KIT or PDGFRA. Transient disease control in the first-line setting is achieved via inhibition of tyrosine kinase signaling using the KIT inhibitor imatinib. [...]

13 Apr, 2022

2022 AACR: A high sensitivity, tumor-informed liquid biopsy platform, designed to detect minimal residual disease at part per million resolution

2022 AACR: A high sensitivity, tumor-informed liquid biopsy platform, designed to detect minimal residual disease at part per million resolution Overview Tumor-informed liquid biopsy approaches have proven promising for detecting minimal residual disease (MRD) and recurrence of cancer following surgical resection or other therapy. However, current liquid biopsy MRD assays typically detect ctDNA in a [...]

13 Apr, 2022

2022 AACR: Mono-allelic immunopeptidomics data from 109 MHC-I alleles reveals variability in binding preferences and improves neoantigen prediction algorithm

2022 AACR: Mono-allelic immunopeptidomics data from 109 MHC-I alleles reveals variability in binding preferences and improves neoantigen prediction algorithm Overview  This study extends the previously published MHC-I, pan-allelic neoantigen prediction algorithm, SHERPA™, with immunopeptidomics from 84 additional mono-allelic transfected cell lines, totaling data from 109 unique alleles. SHERPA achieves model generalizability and 98% population [...]

2 Feb, 2022

Personalis at Liquid Biopsy for Precision Oncology Summit US 2022

Personalis at Liquid Biopsy for Precision Oncology Summit US: 10th-11th February 2022 NeXT Personal: Next Generation MRD Testing for Solid Tumors February 10: 12:30-1:00 PM PST Dan Norton, MBA Associate Director, Product Management Personalis, Inc. The ability to monitor and predict molecular recurrence [...]

16 Dec, 2021

NeXT Personal™

NeXT Personal™ The Next Generation in Molecular Residual Disease Testing and Variant Monitoring for Solid Tumors Delivering Industry-Leading Sensitivity to Detect Residual Disease and Recurrence at the Earliest Timepoints NeXT Personal, an advanced, personalized, and tumor-informed liquid biopsy assay, is designed to detect molecular residual disease (MRD) and cancer recurrence at [...]

18 Nov, 2021

2021 SITC Online Sponsored Symposium

2021 SITC Online Sponsored Symposium | November 12, 2021 Leveraging comprehensive genomic data for diagnostic capabilities and composite biomarker discovery in immunotherapy Erin Newburn, MS, PhD Director, Field Application Scientist Personalis, Inc. To enable the identification of composite biomarkers that combine tumor- and immune-related information [...]

15 Nov, 2021

2021 SITC: Tumor-informed liquid biopsy monitoring of evolving therapeutic resistance mechanisms in head and neck squamous cell carcinoma patients receiving anti-PD-1 therapy

2021 SITC: Tumor-informed liquid biopsy monitoring of evolving therapeutic resistance mechanisms in head and neck squamous cell carcinoma patients receiving anti-PD-1 therapy Background Typical liquid biopsy panels offer a limited understanding of tumor biology, potentially under-representing the heterogeneity of resistance in late-stage cancers. Here, diminished scope can result in undetected, therapeutically-relevant biomarkers which respond [...]

15 Nov, 2021

2021 SITC: Comprehensive profiling of the tumor-immune microenvironment using an augmented transcriptome

2021 SITC: Comprehensive profiling of the tumor-immune microenvironment using an augmented transcriptome Introduction Comprehensive profiling of both the tumor and tumor microenvironment (TME) can help further our understanding of tumor progression and response to treatment. Many immune features can be extracted from transcriptomic data, including characterization of the immune infiltrate and profiling of the [...]

Go to Top